| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 114.91M | 107.45M | 101.01M | 126.56M | 126.01M | 134.19M |
| Gross Profit | 33.10M | 30.85M | 23.31M | 27.62M | 29.01M | 27.54M |
| EBITDA | 12.57M | 11.06M | 2.60M | 10.07M | 9.15M | 9.44M |
| Net Income | 4.33M | 2.51M | -1.62M | 4.58M | 3.81M | 3.73M |
Balance Sheet | ||||||
| Total Assets | 69.09M | 68.49M | 70.74M | 80.37M | 105.89M | 80.03M |
| Cash, Cash Equivalents and Short-Term Investments | 14.47M | 19.44M | 20.10M | 15.32M | 17.63M | 22.33M |
| Total Debt | 535.00K | 6.67M | 15.51M | 25.49M | 25.82M | 28.34M |
| Total Liabilities | 40.20M | 43.32M | 47.92M | 56.06M | 84.32M | 60.59M |
| Stockholders Equity | 28.90M | 25.17M | 22.81M | 24.30M | 21.57M | 19.44M |
Cash Flow | ||||||
| Free Cash Flow | 8.90M | 13.24M | 13.26M | 297.00K | 1.35M | 9.29M |
| Operating Cash Flow | 10.36M | 14.21M | 14.07M | 1.39M | 3.60M | 10.74M |
| Investing Cash Flow | -1.45M | -928.00K | -724.00K | 531.00K | -1.47M | -1.45M |
| Financing Cash Flow | -14.08M | -10.39M | -11.85M | -4.08M | -6.79M | -15.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$344.60M | 10.02 | 4.09% | 6.78% | 6.84% | -0.96% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
54 Neutral | HK$2.79B | 82.46 | 15.73% | 0.48% | 11.29% | 40.42% | |
54 Neutral | €289.57M | -8.02 | -11.41% | 8.57% | -16.95% | -461.16% | |
46 Neutral | €194.04M | -1.34 | -8.93% | ― | -59.19% | -159.11% | |
46 Neutral | HK$209.10M | -9.65 | -4.14% | ― | 3.70% | 5.90% | |
45 Neutral | HK$598.10M | ― | -16.40% | 4.61% | 0.48% | -86.42% |
Home Control International Limited has successfully completed the placement of 28,424,000 new shares, representing 5.31% of its enlarged share capital, at a price of HK$3.80 per share. The proceeds from this placement will be used to expand into the healthcare sector, where the company plans to develop AIoT technology for personal healthcare management, integrating hardware, software, and services to launch a new brand focused on home healthcare solutions.
Home Control International Limited has announced the placement of 28,424,000 new shares under a general mandate, aiming to raise approximately HK$108 million in gross proceeds. The placement, priced at HK$3.80 per share, represents a significant discount to recent trading prices and is expected to enhance the company’s capital base without requiring shareholder approval, potentially impacting its market positioning and investor relations.
Home Control International Limited has announced a high concentration of its shareholding in the hands of a limited number of shareholders, as revealed by a recent enquiry by the Securities and Futures Commission (SFC). As of October 17, 2025, 91.61% of the company’s shares were held by a small group, including a substantial shareholder, Meta-Wisdom Tech Limited. This concentration could lead to significant price fluctuations, as evidenced by the share price rising 561% from June to November 2025. Stakeholders are advised to exercise caution due to the potential volatility in share prices.
The Securities and Futures Commission (SFC) has announced a high concentration of shareholding in Home Control International Limited, with a small number of shareholders holding a significant portion of the company’s shares. As of October 17, 2025, 91.61% of the issued shares were held by a substantial shareholder and a group of 20 shareholders, leaving only 8.39% for other shareholders. This concentration could lead to substantial price fluctuations, as evidenced by the share price increase of 561% from June to November 2025, prompting the SFC to advise caution for current and prospective investors.
Home Control International Limited has established a wholly-owned subsidiary, Orbiva Limited, in Hong Kong to spearhead its strategic expansion into the healthcare sector. This move is part of the company’s broader strategy to develop an AIoT-enabled home healthcare platform and ecosystem, integrating hardware, software, data, and services. Orbiva Limited will focus on creating intelligent healthcare products and services, aiming to build a comprehensive digital health management system. The company is also exploring partnerships with universities and fintech institutions to enhance its technological and operational capabilities.
Home Control International Limited has announced the incorporation of a wholly-owned subsidiary in Hong Kong as part of its strategic expansion into the healthcare sector. This move aims to leverage the company’s expertise in home-control solutions to develop a comprehensive health-services ecosystem, focusing on home-care scenarios and innovative healthcare operations. The initiative aligns with global trends of population aging and rising chronic diseases, and the company has already seen preliminary success with healthcare solutions accounting for 19.7% of its total revenue in the first half of 2025.